640 related articles for article (PubMed ID: 8768919)
1. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
[TBL] [Abstract][Full Text] [Related]
2. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
[TBL] [Abstract][Full Text] [Related]
3. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
[TBL] [Abstract][Full Text] [Related]
4. A review of the first year of Medicare coverage of erythropoietin.
Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
[TBL] [Abstract][Full Text] [Related]
5. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
Cotter DJ; Thamer M; Kimmel PL; Sadler JH
Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
[TBL] [Abstract][Full Text] [Related]
6. Unequal access to cadaveric kidney transplantation in California based on insurance status.
Thamer M; Henderson SC; Ray NF; Rinehart CS; Greer JW; Danovitch GM
Health Serv Res; 1999 Oct; 34(4):879-900. PubMed ID: 10536975
[TBL] [Abstract][Full Text] [Related]
7. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients.
Powe NR; Griffiths RI; Watson AJ; Anderson GF; de Lissovoy G; Greer JW; Herbert RJ; Milam RA; Whelton PK
J Am Soc Nephrol; 1994 Jan; 4(7):1455-65. PubMed ID: 8161727
[TBL] [Abstract][Full Text] [Related]
8. Excluded from universal coverage: ESRD patients not covered by Medicare.
Thamer M; Ray NF; Richard C; Greer JW; Pearson BC; Cotter DJ
Health Care Financ Rev; 1995; 17(2):123-46. PubMed ID: 10157372
[TBL] [Abstract][Full Text] [Related]
9. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
10. Effect of insurance on prescription drug use by ESRD beneficiaries.
Shih YC
Health Care Financ Rev; 1999; 20(3):39-54. PubMed ID: 10558019
[TBL] [Abstract][Full Text] [Related]
11. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
12. Implications of Medicare Part D in CKD anemia treatment.
Stefanacci RG
J Am Med Dir Assoc; 2006 Nov; 7(9 Suppl):S13-6; quiz S17-21. PubMed ID: 17098632
[TBL] [Abstract][Full Text] [Related]
13. Health Insurance and the Use of Peritoneal Dialysis in the United States.
Perez JJ; Zhao B; Qureshi S; Winkelmayer WC; Erickson KF
Am J Kidney Dis; 2018 Apr; 71(4):479-487. PubMed ID: 29277511
[TBL] [Abstract][Full Text] [Related]
14. Trends in anemia at initiation of dialysis in the United States.
Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
[TBL] [Abstract][Full Text] [Related]
15. Dually eligible individuals with AIDS: characteristics and health services use.
Sambamoorthi U; Collins S; Crystal S
J Health Soc Policy; 2001; 14(1):19-35. PubMed ID: 11374296
[TBL] [Abstract][Full Text] [Related]
16. Assessment of pure red cell aplasia in US dialysis patients: the limits of the Medicare data.
Collins AJ; Li S; Adamson JW; Gilbertson DT
Am J Kidney Dis; 2004 Mar; 43(3):464-70. PubMed ID: 14981604
[TBL] [Abstract][Full Text] [Related]
17. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
House AA; Pham B; Pagé DE
Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
[TBL] [Abstract][Full Text] [Related]
18. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.
Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243
[TBL] [Abstract][Full Text] [Related]
19. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
Powe NR; Griffiths RI; Bass EB
J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
[TBL] [Abstract][Full Text] [Related]
20. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
